Paper - WANFANG MED ONLINE

You Position: Home > Paper

Current insights into the role of HIF-PHD axis in renal anemia

( views:82, downloads:0 )

Author:: No author available

Journal Title:: Acta Physiologica Sinica

Issue:: 6

DOI:: 10.13294/j.aps.2018.0058

Key Word:: 低氧诱导因子;脯氨酰羟化酶;低氧诱导因子-脯氨酸羟化酶轴;肾性贫血

Abstract：肾性贫血是慢性肾脏病患者最常见的并发症之一,主要由促红细胞生成素(erythropoietin,EPO)缺乏和功能性铁缺乏(functional iron deficiency,FID)引起.低氧诱导因子(hypoxia-inducible factor,HIF)是体内参与细胞低氧应答的主要转录因子,而氧依赖性的脯氨酸羟化酶(prolyl hydroxylase,PHD)是HIF降解反应的限速酶,可羟基化HIF的脯氨酸残基,使HIF被蛋白酶体降解,这就是HIF-PHD氧传感途径,亦称HIF-PHD轴.贫血情况下组织缺氧,通过调节HIF-PHD轴可刺激EPO生成、调节铁代谢等,这已成为治疗肾性贫血的新方法.近年来,几种作为选择性HIF-PHD抑制剂的创新药物被成功开发,其中一些药物正在进行临床试验.本文就HIF-PHD轴的概念、调节机制及其在肾性贫血中的作用机制研究进展进行综述.

Reference

[1]Singh AK,Szczech L,Reddan D,etc.Correction of anemia with epoetin alfa in chronic kidney disease.[J].2006,355(20).
[2]Cunming, Duan.Hypoxia-inducible factor 3 biology: complexities and emerging themes.[J].2016.
[3]Martin A,Gonzalez FJ,Anderson ER,etc.Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice.[J].2011,140(7).
[4]Minamishima YA,Kaelin-WG Jr,Bronson RT,etc.Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure.[J].2008,111(6).
[5]Kaelin-WG Jr,Ratcliffe PJ.Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.[J].2008,30(4).
[6]G L Semenza.A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation.[J].1992,12(12).
[7]Aapro,M.,Jelkmann,W.,Constantinescu,S.N.,etc.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer[J].2012,106(7).
[8]Zumbrennen-Bullough,K.,Babitt,J.L..The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients[J].2014,29(2).
[9]Gerl, Katharina,Miquerol, Lucile,Todorov, Vladimir T.,etc.Inducible glomerular erythropoietin production in the adult kidney[J].2015,88(6).
[10]Ponka P,Lok CN.Identification of a hypoxia response element in the transferrin receptor gene.[J].1999,274(34).
[11]Higashijima,Y.,Tanaka,T.,Nangaku,M..Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: Raising expectations for exploratory clinical trials[J].2013,8(8).
[12]Bonomini, Mario,Del Vecchio, Lucia,Sirolli, Vittorio,etc.New Treatment Approaches for the Anemia of CKD[J].2016,67(1).
[13]Akizawa, Tadao,Tsubakihara, Yoshiharu,Nangaku, Masaomi,etc.Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects[J].2017,45(2).
[14].Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease[J].2009,8(2).
[15]Rosenberger C,Mandriota S,Jurgensen JS,etc.Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys.[J].2002,13(7).
[16]Provenzano, Robert,Besarab, Anatole,Sun, Chao H.,etc.Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD[J].2016,11(6).
[17]Kotaro, Takeda,Ann, Cowan,Guo-Hua, Fong.Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system.[J].2007,116.
[18]许曼曼,王俊,谢俊霞.低氧诱导因子对铁代谢的调节[J].2017,(5).
[19]Klotzsche-VonAmeln,A.,Prade,I.,Grosser,M.,etc.PHD4 stimulates tumor angiogenesis in osteosarcoma cells via TGF-α[J].2013,11(11).
[20]Sadeesh K, Ramakrishnan,Yatrik M, Shah.Role of Intestinal HIF-2α in Health and Disease.[J].2016.
[21]Shima H,Iriuchishima H,Goda N,etc.Regulation of the HIF-1alpha level is essential for hematopoietic stem cells.[J].2010,7(3).
[22]Schofield, Christopher J.,Chan, Mun Chiang,Ratcliffe, Peter J.,etc.Pharmacological targeting of the HIF hydroxylases - A new field in medicine development[J].2016,47/48.
[23]Dua, Sohan,Wright, Steven,Zeig, Steven,etc.Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6-to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study[J].2016,67(6).
[24]Wang GL,Jiang BH,Rue EA,etc.Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.[J].1995,92(12).
[25]Paliege A,Rosenberger C,Bondke.Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization.[J].2010,77(4).
[26]Burdmann EA,Pfeffer MA,Chen CY.A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.[J].2009,361(21).
[27]Busbridge M,Murphy KG,Maxwell PH,etc.Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease.[J].2009,75(9).
[28]Kallio PJ,Okamoto K,O'Brien S,etc.Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha.[J].1998,17(22).
[29]Haase, Volker H..Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies[J].2017,356(2).
[30]Thede, Kai,Ergueden, Jens-Kerim,Hartung, Ingo V.,etc.Discovery of Molidustat (BAY85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia[J].2018,13(10).
[31]Gruber M,Johnson RS,Hu CJ,etc.Acute postnatal ablation of Hif-2 alpha results in anemia[J].2007,104(7).
[32]Winkler,I.G.,Nowlan,B.,Levesque,J.-P.,etc.Pharmacologic stabilization of HIF-1α increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation[J].2013,121(5).
[33]Pagani A,Camaschella C,Silvestri L.Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis.[J].2008,111(2).
[34]Maxwell, Patrick H.,Eckardt, Kai-Uwe.HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond[J].2016,12(3).
[35]Rastogi, Anjay,Meadowcroft, Amy M.,Cobitz, Alexander R.,etc.Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia[J].2016,27(4).
[36]Martin E.R.,·Smith M.T.,·Maroni B.J..Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease[J].2017,45(5).
[37]Wu, Yue,Jiang, Zhensheng,You, Qidong,etc.Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors[J].2017,25(15).
[38]Semenza, G.L..Hypoxia-inducible factors in physiology and medicine[J].2012,148(3).
[39]Brian, Keith,Randall S, Johnson,M Celeste, Simon.HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.[J].2012,12.
[40]Koury, Mark J.,Haase, Volker H..Anaemia in kidney disease: harnessing hypoxia responses for therapy[J].2015,11(7).
[41]Oshima, Keisuke,Ikeda, Yasumasa,Horinouchi, Yuya,etc.Iron suppresses erythropoietin expression via oxidative stress-dependent hypoxia-inducible factor-2 alpha inactivation[J].2017,97(5).
[42]Chen, Shuyang,Sang, Nianli.Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells[J].2016,117(2).
[43]Haase VH.Hypoxia-inducible factors in the kidney.[J].2006,291(2).
[44]Atkinson, Meredith A.,Warady, Bradley A..Anemia in chronic kidney disease[J].2018,33(2).